๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers Clinical trials Texas
Clinical trial register · United States · industry-sponsored

Clinical Trials in Texas

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors โ€” the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice โ€” all 9094 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 17 Sep 2026, 08:23 UTC
9094
Studies in scope
industry-sponsored, all four open statuses
4935
Recruiting now
open to new participants
2188
Lead sponsors
across recruiting studies
Top states
California 32 Florida 22 New York 13 Illinois 12 Texas 12
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to
12 of 9094 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
NCT07723248Metastatic Castration Resistant Prostate Cancer
ORIC Pharmaceuticals
Phase 3
600
Indiana, North Carolina, Ohio, Texas, Utah
2026-08-03
Recruiting
A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT07719361Metastatic Castration Resistant Prostate Cancer, mCRPC, mCRPC (Metastatic Castration-resistant Prostate Cancer), Prostatic Neoplasms
Flare Therapeutics Inc.
Phase 1
60
California, Massachusetts, Michigan, New Jersey, South Carolina, Tennessee, Texas, Virginia
2026-07-01
Recruiting
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
NCT07365995Metastatic Castration-resistant Prostate Cancer
BioNTech SE
Phase 3
736
Colorado, Florida, Illinois, Maryland, New York, Ohio, Tennessee, Texas
2026-04-22
Recruiting
Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer
NCT07545811Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Castration-resistant Prostate Cancer
Janux Therapeutics
Phase 1
43
California, Missouri, South Carolina, Tennessee, Texas
2026-04-15
Recruiting
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
NCT07288359Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer
Novartis Pharmaceuticals
Phase 1/2
205
Georgia, Tennessee, Texas
2025-12-29
Recruiting
A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT07244341Metastatic Castration-resistant Prostate Cancer
Daiichi Sankyo
Phase 1
60
California, Massachusetts, Michigan, New York, South Carolina, Texas, Virginia, Wisconsin
2025-12-03
Recruiting
A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
NCT07103018Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer Patients, Metastatic Castration-resistant Prostate Cancer, mCRPC, mCRPC
K36 Therapeutics, Inc.
Phase 1
144
California, Florida, Minnesota, New York, North Carolina, Ohio, South Carolina, Texas
2025-11-21
Active, closed
A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer
NCT06318273Metastatic Castration-Resistant Prostate Cancer
AbbVie
Phase 1
152
California, Connecticut, Florida, Illinois, Michigan, North Carolina, Rhode Island, Texas
2024-03-08
Recruiting
A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
NCT06067841Metastatic Castration-resistant Prostate Cancer
Bristol-Myers Squibb
Phase 1
140
California, Florida, Massachusetts, New York, North Carolina, Texas, Washington
2023-10-18
Active, closed
Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).
NCT05219500Metastatic Castration Resistant Prostate Cancer
Fusion Pharmaceuticals Inc.
Phase 2
115
Nebraska, Texas
2021-12-16
Active, closed
A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT02123758Prostatic Neoplasms, Metastatic Castration-Resistant Prostate Cancer
Aragon Pharmaceuticals, Inc.
Phase 1
57
California, Texas
2014-07-09
Rows per page Showing 1–12 of 12
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 17 September 2026. https://priyalifescience.com/clinical-trials-usa/state/texas

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.